ES2078838A1 - Procedimiento para preparar una composicion a base de clozapina. - Google Patents

Procedimiento para preparar una composicion a base de clozapina.

Info

Publication number
ES2078838A1
ES2078838A1 ES09250020A ES9250020A ES2078838A1 ES 2078838 A1 ES2078838 A1 ES 2078838A1 ES 09250020 A ES09250020 A ES 09250020A ES 9250020 A ES9250020 A ES 9250020A ES 2078838 A1 ES2078838 A1 ES 2078838A1
Authority
ES
Spain
Prior art keywords
clozapine
preferentially
procedure
preparing
sweeper
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09250020A
Other languages
English (en)
Other versions
ES2078838B1 (es
Inventor
Volker Fischer
Ronald Paul Mason
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
US Department of Health and Human Services
Original Assignee
Sandoz AG
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG, US Department of Health and Human Services filed Critical Sandoz AG
Publication of ES2078838A1 publication Critical patent/ES2078838A1/es
Application granted granted Critical
Publication of ES2078838B1 publication Critical patent/ES2078838B1/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

PROCEDIMIENTO PARA PREPARAR UNA COMPOSICION FARMACEUTICA A BASE DE CLOZAPINA. COMPRENDE FORMULAR CLOZAPINA Y UN BARREDOR DE RADICALES, TAL COMO ACIDO L-ASCORBICO, PREFERENTEMENTE EN UNA RELACION EN PESO DE 1:3 A 1:40 APROXIMADAMENTE; Y OPCIONALMENTE FORMAR UNA FORMA DE DOSIFICACION UNITARIA PREFERENTEMENTE PARA ADMINISTRACION ORAL, TAL COMO EN FORMA DE UNA TABLETA, CONTENIENDO PREFERENTEMENTE DE 12,5 A 100 MG DE CLOZAPINA Y UNA CANTIDAD EFICAZ DEL BARREDOR DE RADICALES, PREFERENTEMENTE DE 300 A 1000 MG DE ACIDO L-ASCORBICO. LA COMPOSICION ES DE UTILIDAD EN EL TRATAMIENTO CON FARMACOS ANTIPSICOTICOS Y REDUCE LOS EFECTOS DE GRANULOCITOPENIA Y DE AGRANULOCITOSIS OBSERVADOS EN EL TRATAMIENTO CON AGENTES ANTIPSICOTICOS CONVENCIONALES.
ES09250020A 1990-08-20 1991-08-14 Procedimiento para preparar una composicion farmaceutica a base de clozapina. Expired - Lifetime ES2078838B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56968990A 1990-08-20 1990-08-20
US71713691A 1991-06-18 1991-06-18

Publications (2)

Publication Number Publication Date
ES2078838A1 true ES2078838A1 (es) 1995-12-16
ES2078838B1 ES2078838B1 (es) 1997-02-01

Family

ID=27075116

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09250020A Expired - Lifetime ES2078838B1 (es) 1990-08-20 1991-08-14 Procedimiento para preparar una composicion farmaceutica a base de clozapina.

Country Status (30)

Country Link
US (2) US5312819A (es)
JP (1) JPH0813745B2 (es)
KR (1) KR100189349B1 (es)
AT (1) AT400522B (es)
AU (1) AU649269B2 (es)
BE (1) BE1006878A5 (es)
CA (1) CA2065421A1 (es)
CH (1) CH684162A5 (es)
CZ (1) CZ281843B6 (es)
DE (1) DE4191979T (es)
DK (1) DK51292A (es)
ES (1) ES2078838B1 (es)
FI (1) FI913888A7 (es)
FR (1) FR2665835B1 (es)
GB (1) GB2254252B (es)
GR (1) GR1002188B (es)
HU (1) HUT60137A (es)
IE (1) IE66121B1 (es)
IL (1) IL99224A (es)
IT (1) IT1251226B (es)
LU (1) LU88099A1 (es)
MX (1) MX9100742A (es)
MY (1) MY107976A (es)
NL (1) NL9120006A (es)
NZ (1) NZ239464A (es)
PT (1) PT98707B (es)
RU (1) RU2080860C1 (es)
SE (1) SE9201189D0 (es)
SK (1) SK279225B6 (es)
WO (1) WO1992003138A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2935292A (en) * 1991-10-31 1993-06-07 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Prevention of drug-induced agranulocytosis with free radical scavengers
US5538965A (en) * 1993-12-23 1996-07-23 Allelix Biopharmaceuticals Inc. Dopamine receptor ligands
CA2167104A1 (en) * 1995-01-17 1996-07-18 Joerg G.D. Birkmayer Nadh and nadph therapeutic agents for nasal, sublingual, rectal and dermal administration
JP3889481B2 (ja) * 1996-08-16 2007-03-07 株式会社カネカ 医薬組成物
ATE317226T1 (de) * 1997-10-27 2006-02-15 Cortex Pharma Inc Behandlung der schizophrenie mit ampakinen und neuroleptika
US8753675B1 (en) * 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
JP2003026567A (ja) * 2001-05-10 2003-01-29 Kanegafuchi Chem Ind Co Ltd 補酵素ｑを有効成分とする粘膜投与用組成物
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US8173637B2 (en) * 2008-07-24 2012-05-08 Handa Pharmaceuticals, Llc Stabilized atypical antipsychotic formulation
RU2441651C1 (ru) * 2010-12-23 2012-02-10 Маргарита Алексеевна Морозова Способ получения фармацевтической композиции клозапина в виде таблеток и фармацевтическая композиция
RU2610169C2 (ru) 2014-09-11 2017-02-08 Общество С Ограниченной Ответственностью "Валентек" ПРОИЗВОДНЫЕ 7-ФТОРО-8-ХЛОРО-5Н-ДИБЕНЗО[b, е][1, 4]ДИАЗЕПИНА И ИХ ПРИМЕНЕНИЕ

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI50242C (fi) * 1969-07-18 1976-01-12 Thomae Gmbh Dr K Menetelmä valmistaa farmakologisesti aktiivisia uusia diallyyliaminoal kanoyylidibenso- tai pyridobenso-diatsepiineja ja niiden happoadditios uoloja.
US3983234A (en) * 1974-07-04 1976-09-28 Sandoz Ltd. Treatment of dyskinesias
US4028467A (en) * 1975-01-07 1977-06-07 Berger Frank M Analgesic compositions comprising levo-propoxyphene and benzo diazepine and process
GB1498857A (en) * 1975-07-03 1978-01-25 Leo Ab Antidepressant composition
FI803030A7 (fi) * 1979-10-01 1981-01-01 Sandoz Ag Dibentsatsepiinijohdannaiset, niiden tuotanto ja niitä sisältävät farmaseuttiset yhdistelmät.
US4761411A (en) * 1983-05-18 1988-08-02 Hoechst-Roussel Pharmaceuticals Inc. Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses
DE3542309A1 (de) * 1985-11-29 1987-06-04 Cardona Federico Dr Medizinisches antioxidativum
US4973586A (en) * 1986-01-16 1990-11-27 Schering Corporation Fused benzazepines, compositions of, and medical use thereof
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
CA1327008C (en) * 1988-01-15 1994-02-15 Walter Merz Anti-psychotic imidazobenzodiazepine
US4996199A (en) * 1988-04-08 1991-02-26 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
JP2903318B2 (ja) * 1989-04-04 1999-06-07 日研フード株式会社 抗酸化的ストレス物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEM. ABS. Vol. 109, N‘ 25, 19 de Diciembre de 1988, Columbus, Ohio, U.S.A.), pßg. 709, resumen n‘ 229245a, MIELE et al "New views on the role of ascorbic acid in the central nervous system", Clin. Ter. 1988, 125(1), 3-14 (Roma) *

Also Published As

Publication number Publication date
CH684162A5 (de) 1994-07-29
MX9100742A (es) 1992-04-01
PT98707B (pt) 1999-01-29
GB9206101D0 (en) 1992-06-24
FI913888A0 (fi) 1991-08-16
GB2254252B (en) 1994-06-01
DE4191979T (es) 1992-10-08
JPH05503296A (ja) 1993-06-03
DK51292D0 (da) 1992-04-15
WO1992003138A1 (en) 1992-03-05
AU649269B2 (en) 1994-05-19
CS55092A3 (en) 1992-08-12
IT1251226B (it) 1995-05-05
SE9201189L (sv) 1992-04-14
KR100189349B1 (en) 1999-06-01
MY107976A (en) 1996-07-15
HUT60137A (en) 1992-08-28
DK51292A (da) 1992-04-15
ITMI912261A1 (it) 1993-02-20
AU8396391A (en) 1992-03-17
JPH0813745B2 (ja) 1996-02-14
US5312819A (en) 1994-05-17
CZ281843B6 (cs) 1997-02-12
IE912934A1 (en) 1992-02-26
SK279225B6 (sk) 1998-08-05
RU2080860C1 (ru) 1997-06-10
PT98707A (pt) 1992-07-31
GB2254252A (en) 1992-10-07
FR2665835B1 (fr) 1995-06-23
IE66121B1 (en) 1995-12-13
HU9201090D0 (en) 1992-06-29
US5563134A (en) 1996-10-08
FI913888L (fi) 1992-02-21
BE1006878A5 (fr) 1995-01-17
LU88099A1 (de) 1992-11-16
SE9201189D0 (sv) 1992-04-14
NL9120006A (nl) 1992-08-03
ES2078838B1 (es) 1997-02-01
ATA900491A (de) 1995-06-15
ITMI912261A0 (it) 1991-08-20
KR920702225A (ko) 1992-09-03
IL99224A0 (en) 1992-07-15
NZ239464A (en) 1993-10-26
FI913888A7 (fi) 1992-02-21
GR1002188B (en) 1996-03-13
AT400522B (de) 1996-01-25
CA2065421A1 (en) 1992-02-21
IL99224A (en) 1996-01-31
GR910100361A (el) 1992-08-31
FR2665835A1 (fr) 1992-02-21

Similar Documents

Publication Publication Date Title
CO5261517A1 (es) Composiciones farmaceuticas analgesicas que contienen buprenorfina/naloxona, buprenorfina/naltrexona o buprenorfina/nalmefen en bajas dosis
DE69027216D1 (de) Transmukosale dosisform
DE69427708D1 (de) Stabilisierte arzneizusammensetzung enthaltend 10-hydroxy-7-ethylcamptothecin als lakton-verbindung
ES2188782T3 (es) Formulaciones farmaceuticas que contienen darifenacina.
MX171191B (es) Composiciones farmaceuticas de glipizida
IL91656A0 (en) Pharmaceutical composition containing a benzodiazepine derivative
IT8767796A0 (it) Forma farmaceutica di dosaggio per somministrazione orale con erogazione controllata di un ingrediente attivo
LV10954A (lv) Benzimidazola atvasinajumi to iegusanas panemiens un tos saturosa farmaceitiska kompozicija
LU90677I2 (fr) Esomeprazole et ses sels et d-riv-s pharmaceutiquement acceptables (nexiam)
PT100635A (pt) Forma de dosagem farmaceutica para a administracao retardada de um farmaco
ES2078838A1 (es) Procedimiento para preparar una composicion a base de clozapina.
AR019053A1 (es) Uso de 2'2'-difluoronucleosidos para la preparacion de un medicamento y composicion farmaceutica y producto farmaceutico que los contienen
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
KR970025615A (ko) 암 전이 억제제
ES2175663T3 (es) Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.
ES2119748T3 (es) Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
ES2108130T3 (es) Formulaciones farmacologicas mejoradas.
GR3019274T3 (en) Substituted 3-piperazinylalkyl-2,3-dihydro-4H-1,3-benzoxazine-4-ones, their preparation and their therapeutical use
FR2699176B1 (fr) Nouveaux composés bicycliques de pyrimidine, leur procédé de préparation et les compositions pharmaceutiques les renfermant.
DE69322411D1 (de) Arzneizusammensetzungen enthaltend tandospiron oder seine analoge
OA07029A (fr) Le chlorure de gallium, nouveau médicament anti-cancéreux.
KR890004705A (ko) 항바이러스성 제제
KR890007740A (ko) 제약학적 조성물
ES2067206T3 (es) Composiciones farmaceuticas conteniendo 3-amino-epsilon-caprolactamas para estimular el proceso de aprendizaje y la memoria.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19910814

Kind code of ref document: B1

Effective date: 19910814

PC2A Transfer of patent